| Name | Title | Contact Details |
|---|
As thriving, and in-demand executive leaders, the Churchstreeter and Crosse approach is grounded in catering to our exclusive family of clients. The Executive leaders of Churchstreeter and Crosse envisioned a new way of consulting. They decided that percentage based contracts were great for C&C, but not great for our family of clients. Our goal has always been to create partnerships that withstand the test of time. We transitioned to a bold new style of consulting in order to compete in a space where there was a void. Our annual client engagements are exclusive, and we dont compete within the same space, when we have an exclusive agreement. Our goal has never been to be the biggest, our goal is simply to be the best. With a waiting list of engagements, we know that we have created an amazing value proposition. Our engagement assessment is comprehensive. You will feel the difference immediately. The Churchstreeter and Crosse comprehensive proposal process includes a project plan with timeline, milestones, cost/benefit analysis, and a clear financial agreement based on your goals. We also offer a suite of quality products that will help you get there, quickly and smoothly. Thats how we ensure your success. Our Mission: To deliver the best to our exclusive family of clients and retain the most specialized talent.
The Siegfried Group is a Philadelphia, PA-based company in the Business Services sector.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.